Hutchmed Launches Global Trial of HMPL-A580 in Patients With Solid Tumors

MT Newswires Live

03/04

Hutchmed (HCM) said Wednesday it has started a phase I/IIa clinical trial of its HMPL-A580 antibody-targeted therapy conjugate candidate in certain cancer patients in the US and China.

The trial covers patients with unresectable, advanced or metastatic solid tumors.

In phase I, patients will receive HMPL-A580 intravenously at predefined dose levels to help determine the maximum tolerated dose and recommended dose for expansion.

Phase IIa will help further characterize the candidate's safety, tolerability and preliminary anti-tumor activity in selected solid tumors, and determine the recommended dose for the next phase, the company said.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2616390515"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616390515\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616390515?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 18:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616390515","market":"us","top_or_hot":-1,"title":"Hutchmed Launches Global Trial of HMPL-A580 in Patients With Solid Tumors","media":"MT Newswires Live","content":"<html><body><p> Hutchmed (HCM) said Wednesday it has started a phase I/IIa clinical trial of its HMPL-A580 antibody-targeted therapy conjugate candidate in certain cancer patients in the US and China.</p><p>The trial covers patients with unresectable, advanced or metastatic solid tumors.</p><p>In phase I, patients will receive HMPL-A580 intravenously at predefined dose levels to help determine the maximum tolerated dose and recommended dose for expansion.</p><p>Phase IIa will help further characterize the candidate's safety, tolerability and preliminary anti-tumor activity in selected solid tumors, and determine the recommended dose for the next phase, the company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hutchmed Launches Global Trial of HMPL-A580 in Patients With Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHutchmed Launches Global Trial of HMPL-A580 in Patients With Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-04 18:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Hutchmed (HCM) said Wednesday it has started a phase I/IIa clinical trial of its HMPL-A580 antibody-targeted therapy conjugate candidate in certain cancer patients in the US and China.</p><p>The trial covers patients with unresectable, advanced or metastatic solid tumors.</p><p>In phase I, patients will receive HMPL-A580 intravenously at predefined dose levels to help determine the maximum tolerated dose and recommended dose for expansion.</p><p>Phase IIa will help further characterize the candidate's safety, tolerability and preliminary anti-tumor activity in selected solid tumors, and determine the recommended dose for the next phase, the company said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2616390515","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616390515","pubTimestamp":1772621438,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hutchmed  said Wednesday it has started a phase I/IIa clinical trial of its HMPL-A580 antibody-targeted therapy conjugate candidate in certain cancer patients in the US and China.The trial covers patients with unresectable, advanced or metastatic solid tumors.In phase I, patients will receive HMPL-A580 intravenously at predefined dose levels to help determine the maximum tolerated dose and recommended dose for expansion.Phase IIa will help further characterize the candidate's safety, tolerability and preliminary anti-tumor activity in selected solid tumors, and determine the recommended dose for the next phase, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4531":"中概回港概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","HCM":"和黄医药"},"translate_title":"和黄医药启动HMPL-A580在实体瘤患者中的全球试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCM":1},"content_text":"Hutchmed (HCM) said Wednesday it has started a phase I/IIa clinical trial of its HMPL-A580 antibody-targeted therapy conjugate candidate in certain cancer patients in the US and China.The trial covers patients with unresectable, advanced or metastatic solid tumors.In phase I, patients will receive HMPL-A580 intravenously at predefined dose levels to help determine the maximum tolerated dose and recommended dose for expansion.Phase IIa will help further characterize the candidate's safety, tolerability and preliminary anti-tumor activity in selected solid tumors, and determine the recommended dose for the next phase, the company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}